Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 20 June 2016 | By Zachary Brennan
For those tracking the contentious debate over drug and biologic price hikes in the US, an IMS Health report released on Monday offers the latest evidence yet that a robust biosimilars market can not only lower prices across drug classes but also increase patient uptake of such treatments.
“The increased competition affects not just the price for the directly comparable product but also has an effect on the price of the whole product class,” the report says. “In countries which used to have low usage/availability in the classes, the price reductions seem to have a significant impact on the increased access.”
The report follows the release of a separate report in March noting that biosimilars could save health systems across Europe and the US as much as $110 billion through 2020.
A biosimilar medicinal product is a biologic medicine similar to another biologic medicine that has already been authorized for use in the EU.
Since 2006, the EU has seen the approval of 20 such biosimilars (see below), while only two have been approved in the US, including Celltrion and Pfizer’s Inflectra (infliximab-dyyb), which is biosimilar to Janssen Biotech’s Remicade (infliximab) and Sandoz' Zarxio (filgrastim-sndz), which is biosimilar to Amgen's Neupogen (filgrastim).
The EU is also out-pacing the US in terms of which biosimilars are under review:
The new report tracks the uptake and price reductions across four classes of treatments – Epoteins (EPOs), injectables that can treat anemia, granulocyte-colony stimulating factor (G-CSF), which can be used to accelerate recovery from neutropenia linked to chemotherapy treatment for cancer patients, human growth hormone (HGH), which stimulates growth; and anti-tumor necrosis factor (anti-TNF) drugs that are used to treat inflammatory conditions – that have seen varying levels of biosimilar approvals.
“For the 4 classes we can see the same pattern; high savings can be achieved even if biosimilar uptake is low,” the report says.
And these price reductions are not just seen for the directly comparable products but for the entire product class.
However, like in the US, which has been careful to approve biosimilars only for indications that prove viable from clinical trials, the report notes the differences in approved indications are relatively small for HGH and G-CSF treatments, somewhat larger for EPOs and the largest for Anti-TNF, which has only seen the launch in February of the first entanercept biosimilar (known as Benepali) referencing Enbrel and which has just been launched by Samsung Bioepis (joint venture between Samsung and Biogen) in Norway, Germany, UK and Sweden.
“As a result, different products are used for different indications, which impact the patients for which they compete in the class. This is most obvious in Anti-TNF. Frequency of administration and mode of administration also impact the competition within a class,” the report says.
An updated question and answer document on biosimilars is expected to be released by the end of June from the European Commission, according to a presentation of the IMS report in Brussels at a stakeholder conference.
The impact on biosimilar competition on price, volume and market share - updated version 2016
Tags: biosimilars, EU uptake of biosimilar medicinal products, IMS Health, EPO, Anti-TNF, Humira, Enbrel, Remicade
Regulatory Focus newsletters
All the biggest regulatory news and happenings.